article
Game-changing pan-TEAD inhibitor for solid tumours
Insilico Medicine has announced the nomination of ISM6331 as a potential best-in-class pan-TEAD inhibitor for the treatment of advanced solid tumours.
List view / Grid view
Cell-based assays
article
Neoantigen-directed cancer treatment
This exclusive interview with Dr Sharon Benzeno, Chief Commercial Officer, Immune Medicine at Adaptive Biotechnologies, explores research on T-cell therapy for cancer, which has seen the first TCR-based therapeutic candidate progress to clinical development, offering promising advancements in innovative cancer treatments.
article
ebook: Advances In Cell Imaging and Retrieval
Unleash the power of drug discovery with this FREE ebook supported by Sartorius! Explore the limitless potential of CRISPR applications and single cell sequencing for drug discovery. Access exclusive insights from industry leaders and stay ahead of the curve with the latest trends. Don't miss out on this opportunity to…
webinar
Validated bioassays for metabolic & gastrointestinal diseases: Accelerating development of GLP-1 & -2 therapeutics
20 December 2022 | By Eurofins DiscoverX Corp.
In this webinar, we present an approach for building MOA-based, simple, ready-to-use GLP-1 and GLP-2 bioassays and discuss assay validation results from Eurofins BPT.
whitepaper
Product hub: Targeted protein degradation – next-generation therapeutics
Helen Harrison, Director of Screening at Amphista Therapeutics, discusses targeted protein degradation (TPD) and the discovery of drugs in this area.
webinar
Roundtable: Accelerating your biologics therapeutics development with bioassays
9 June 2022 | By Eurofins DiscoverX
Watch this on-demand virtual roundtable to explore how the simple, thaw-and-use bioassay format improves assay workflow and helps attain high assay reproducibility.
article
Uniting industry and academia for phenotypic drug discovery
A collaboration between Exscientia and the University of Oxford Target Discovery Institute (Oxford TDI) has been established to source cellular functional assays from the global academic community, with the goal of developing novel screens and identifying targets and therapeutic candidates for unmet medical needs. Here, Dr Denise Barrault, Director of…
news
Cell survival mechanisms identified through RNA regulation in central nervous system
A new study from Niigata University has found a binding protein that is vital for proper development of the central nervous system.
news
Plant-derived antiviral drug could combat Delta variant
A novel antiviral drug called thapsigargin (TG) blocked COVID-19 infection in cells, including all new variants, in a pre-clinical study.
news
Rheumatoid arthritis discovery may lead to novel inflammation blockers
A new study links tumour necrosis factor seen in rheumatoid arthritis with T cell dysfunction, potentially leading to new therapies.
news
Altered fat metabolism shown to play a key role in ALS
Scientists reveal that higher levels of inflammatory chemicals involved in fat metabolism occur in people with amyotrophic lateral sclerosis.
news
Ncardia secures more than $60 million to enhance and expand leading iPSC offerings
Ncardia has formed a strategic partnership with Kiniciti to build GMP capabilities to support iPSC cell therapy platforms and human cell-based in vitro discovery services.
news
Nanoscale “computer” a pivotal step for precision medicine
The study paves the way for the construction of complex nanoscale computers for the prevention and treatment of cancer and other diseases.
news
Targeting channel in cell lysosome could selectively kill cancer cells
Activating the protein channel TRPML1 induced selective melanoma cell death while sparing normal cells, suggesting a potential pathway for new cancer therapies.
webinar
Cardiac proarrhythmic risk assessment using human-induced pluripotent stem cell-derived cardiomyocytes
19 August 2021 | By Eurofins Discovery
Watch this on-demand webinar that discusses the two assays developed by Eurofins and why they represent a more physiologic and dynamic system to provide a more comprehensive pre-clinical model for cardiac liability assessment.
